Herbert Kellner

2.2k total citations
38 papers, 1.2k citations indexed

About

Herbert Kellner is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Herbert Kellner has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Rheumatology, 15 papers in Hematology and 9 papers in Immunology. Recurrent topics in Herbert Kellner's work include Rheumatoid Arthritis Research and Therapies (25 papers), Autoimmune and Inflammatory Disorders Research (15 papers) and Spondyloarthritis Studies and Treatments (13 papers). Herbert Kellner is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (25 papers), Autoimmune and Inflammatory Disorders Research (15 papers) and Spondyloarthritis Studies and Treatments (13 papers). Herbert Kellner collaborates with scholars based in Germany, United States and Switzerland. Herbert Kellner's co-authors include Patrick Durez, Eva Dokoupilová, Mark C. Genovese, Sophie Hugot, Christine E. Codding, Hanno B. Richards, Shephard Mpofu, Sang‐Heon Lee, Jerzy Supronik and Takashi Ikawa and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the New York Academy of Sciences and Annals of the Rheumatic Diseases.

In The Last Decade

Herbert Kellner

34 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Herbert Kellner Germany 17 762 523 307 137 123 38 1.2k
Tatiana Cobo‐Ibáñez Spain 18 719 0.9× 331 0.6× 212 0.7× 107 0.8× 102 0.8× 34 1.0k
P. Nicaise‐Roland France 24 931 1.2× 396 0.8× 262 0.9× 111 0.8× 156 1.3× 56 1.5k
Marijn Vis Netherlands 20 997 1.3× 498 1.0× 337 1.1× 243 1.8× 151 1.2× 68 1.5k
Bernard Vandooren Belgium 17 863 1.1× 633 1.2× 354 1.2× 268 2.0× 56 0.5× 26 1.4k
Predrag Musikic Slovenia 10 744 1.0× 308 0.6× 322 1.0× 259 1.9× 135 1.1× 12 1.2k
Giusy Peluso Italy 18 581 0.8× 290 0.6× 205 0.7× 137 1.0× 79 0.6× 42 1.1k
Yannick Degboé France 20 563 0.7× 342 0.7× 214 0.7× 231 1.7× 53 0.4× 70 1.1k
A. Nzeusseu Toukap Belgium 14 549 0.7× 226 0.4× 144 0.5× 104 0.8× 83 0.7× 36 784
Kotaro Otomo Japan 17 752 1.0× 429 0.8× 254 0.8× 125 0.9× 110 0.9× 38 1.2k
Henrik Skjødt Denmark 20 647 0.8× 208 0.4× 187 0.6× 239 1.7× 83 0.7× 34 1.2k

Countries citing papers authored by Herbert Kellner

Since Specialization
Citations

This map shows the geographic impact of Herbert Kellner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herbert Kellner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herbert Kellner more than expected).

Fields of papers citing papers by Herbert Kellner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herbert Kellner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herbert Kellner. The network helps show where Herbert Kellner may publish in the future.

Co-authorship network of co-authors of Herbert Kellner

This figure shows the co-authorship network connecting the top 25 collaborators of Herbert Kellner. A scholar is included among the top collaborators of Herbert Kellner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herbert Kellner. Herbert Kellner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kellner, Herbert, et al.. (2024). CPPD—differential diagnostics and differential therapeutic challenges. SHILAP Revista de lepidopterología. 2(6). 443–460.
2.
3.
Regierer, Anne C., Anja Weiß, Uta Kiltz, et al.. (2022). The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study. The Journal of Rheumatology. 50(2). 185–191. 3 indexed citations
4.
Foldenauer, Ann Christina, Rieke Alten, Martin Aringer, et al.. (2022). Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). Journal of Clinical Medicine. 11(24). 7316–7316. 1 indexed citations
5.
Mease, Philip J., Herbert Kellner, Akimichi Morita, et al.. (2022). Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial. Rheumatology and Therapy. 9(5). 1361–1375. 11 indexed citations
6.
Behrens, Frank, Gerd‐Rüdiger Burmester, Martin Feuchtenberger, et al.. (2022). Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clinical and Experimental Rheumatology. 40(3). 551–559. 11 indexed citations
7.
Foldenauer, Ann Christina, Eva Herrmann, Gerd R Burmester, et al.. (2022). Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. The Lancet Rheumatology. 5(1). e14–e23. 10 indexed citations
8.
Visvanathan, Sudha, Ulf Müller‐Ladner, Meera Ramanujam, et al.. (2019). Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Annals of the Rheumatic Diseases. 78(6). 754–760. 44 indexed citations
9.
Genovese, Mark C., Patrick Durez, Hanno B. Richards, et al.. (2014). One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. The Journal of Rheumatology. 41(3). 414–421. 83 indexed citations
10.
Kellner, Herbert. (2014). Rheuma oder kein Rheuma?. MMW - Fortschritte der Medizin. 156(11). 41–43.
11.
Schäfer, Valentin Sebastian, Martin Fleck, Herbert Kellner, et al.. (2013). Evaluation of the novel ultrasound score for large joints in psoriatic arthritis and ankylosing spondylitis: six month experience in daily clinical practice. BMC Musculoskeletal Disorders. 14(1). 358–358. 18 indexed citations
12.
Genovese, Mark C., Patrick Durez, Hanno B. Richards, et al.. (2012). Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Annals of the Rheumatic Diseases. 72(6). 863–869. 227 indexed citations
13.
Backhaus, Tina, Sarah Ohrndorf, Herbert Kellner, et al.. (2012). The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy. Annals of the Rheumatic Diseases. 72(7). 1163–1169. 71 indexed citations
14.
Alten, Rieke, Juan J. Gómez‐Reino, Patrick Durez, et al.. (2011). Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskeletal Disorders. 12(1). 153–153. 114 indexed citations
15.
Hartung, Wolfgang, Herbert Kellner, Johannes Strunk, et al.. (2011). Development and evaluation of a novel ultrasound score for large joints in rheumatoid arthritis: One year of experience in daily clinical practice. Arthritis Care & Research. 64(5). 675–682. 58 indexed citations
16.
Kellner, Herbert, et al.. (2010). Leflunomide in the treatment of patients with early rheumatoid arthritis—results of a prospective non-interventional study. Clinical Rheumatology. 29(8). 913–920. 25 indexed citations
17.
Rihl, Markus, Herbert Kellner, David Tak Yan Yu, et al.. (2008). Identification of interleukin‐7 as a candidate disease mediator in spondylarthritis. Arthritis & Rheumatism. 58(11). 3430–3435. 32 indexed citations
18.
19.
Weidner, Sven, et al.. (2004). Interventional radiology and the musculoskeletal system. Best Practice & Research Clinical Rheumatology. 18(6). 945–956. 20 indexed citations
20.
Kellner, Herbert. (1985). Las cooperativas agrarias en la Comunidad Europea. 74–79. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tatiana Cobo‐Ibáñez Breakdown of academic impact, for papers by P. Nicaise‐Roland Breakdown of academic impact, for papers by Marijn Vis Breakdown of academic impact, for papers by Bernard Vandooren Breakdown of academic impact, for papers by Predrag Musikic Breakdown of academic impact, for papers by Giusy Peluso Breakdown of academic impact, for papers by Yannick Degboé Breakdown of academic impact, for papers by A. Nzeusseu Toukap Breakdown of academic impact, for papers by Kotaro Otomo Breakdown of academic impact, for papers by Henrik Skjødt
Rankless by CCL
2026